Rowley S D, Prather K, Bui K T, Appel M, Felt T, Bensinger W I
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA.
Transfusion. 1999 Nov-Dec;39(11-12):1200-6. doi: 10.1046/j.1537-2995.1999.39111200.x.
Apheresis devices designed for the collection of mature blood elements are being used for the collection of peripheral blood progenitor cells (PBPCs). The collection of PBPCs differs from that of other cells in the rarity of the target cell and in the fact that donors may undergo several days of collection. A consequence of this process may be a depletion of blood cells such as platelets from the blood. The disposable set and operating software for an apheresis device (Spectra, COBE BCT) was modified by the manufacturer to automate the collection of PBPCs and reduce the collection of unwanted blood cells.
A study was initiated to compare the collection of PBPCs with the new device, the AutoPBSC (version [V]6.0 with AutoPBSC tubing set), and that with the MNC (mononuclear cell) procedure (V4.7 with white cell tubing set), for patients and healthy donors.
Patients whose blood was processed by either theV6.0 orV4.7 procedure achieved the target dose of 5 x 10(6) CD34+ cells per kg of patient weight in similar numbers of procedures, even though the calculated collection efficiency for CD34+ cells using the automated V6.0 procedure was significantly less than that with the V4.7 procedure for both allogeneic donors and patients donating PBPCs. The collection efficiency for platelets was lower with the V6.0 procedure, and components collected in this manner contained fewer platelets. Apheresis by the V6.0 procedure required 30 to 60 more minutes per procedure than apheresis by the V4.7 procedure. Review of engraftment kinetics after transplantation did not reveal any effect of the collection procedure on recipients of either allogeneic or autologous transplants.
The collection efficiencies of the V6.0 procedure for both CD34+ cells and mature blood cells are lower than those of the V4.7 procedure. The lower collection efficiency for platelets results in a smaller drop in peripheral blood platelet count after the procedure. The automated features of the V6.0 procedure may simplify PBPC collection, but this procedure requires a longer apheresis.
设计用于采集成熟血细胞的血液成分分离装置正被用于采集外周血祖细胞（PBPC）。PBPC的采集与其他细胞采集的不同之处在于目标细胞稀少，且供体可能要经历数天的采集过程。这个过程的一个后果可能是血液中血细胞如血小板的消耗。血液成分分离装置（Spectra，COBE BCT）的一次性套件和操作软件由制造商进行了改进，以实现PBPC采集自动化并减少不需要的血细胞采集。
开展了一项研究，比较新装置AutoPBSC（版本[V]6.0及AutoPBSC管路套件）和MNC（单核细胞）程序（V4.7及白细胞管路套件）对患者和健康供体采集PBPC的情况。
采用V6.0或V4.7程序处理血液的患者，在相似的采集次数下均达到了每千克患者体重5×10⁶个CD34⁺细胞的目标剂量，尽管对于同种异体供体和捐献PBPC的患者，使用自动化V6.0程序计算的CD34⁺细胞采集效率显著低于V4.7程序。V6.0程序的血小板采集效率较低，以这种方式采集的成分中血小板较少。V6.0程序的血液成分分离每次操作比V4.7程序多需要30至60分钟。对移植后植入动力学的回顾未发现采集程序对同种异体或自体移植受者有任何影响。
V6.0程序对CD34⁺细胞和成熟血细胞的采集效率均低于V4.7程序。血小板采集效率较低导致采集后外周血血小板计数下降幅度较小。V6.0程序的自动化功能可能简化PBPC采集，但该程序需要更长的血液成分分离时间。
